AU2002330108A1 - 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer - Google Patents

2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer

Info

Publication number
AU2002330108A1
AU2002330108A1 AU2002330108A AU2002330108A AU2002330108A1 AU 2002330108 A1 AU2002330108 A1 AU 2002330108A1 AU 2002330108 A AU2002330108 A AU 2002330108A AU 2002330108 A AU2002330108 A AU 2002330108A AU 2002330108 A1 AU2002330108 A1 AU 2002330108A1
Authority
AU
Australia
Prior art keywords
substtituded
aminopyrimidines
cancer
treatment
kinase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002330108A
Inventor
Cheng Bi
Stephen Boyer
Jennifer Burke
Michael J. Burke
Jianqing Chen
Yuanwei Chen
Roger B. Clark
James Cook
Jianmei Fan
Gaetan Ladouceur
Dhanapalan Nagarathnam
Barton Phillips
Sharad K. Verma
Chunguang Wang
Olaf Weber
Lin Yi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of AU2002330108A1 publication Critical patent/AU2002330108A1/en
Abandoned legal-status Critical Current

Links

AU2002330108A 2001-09-25 2002-09-25 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer Abandoned AU2002330108A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60/324,276 2001-09-25
US60/352,509 2002-01-31

Publications (1)

Publication Number Publication Date
AU2002330108A1 true AU2002330108A1 (en) 2003-04-22

Family

ID=

Similar Documents

Publication Publication Date Title
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
HK1092377A1 (en) Preparation for the prophylaxis of restenosis
AU2002328092A1 (en) Bicyclic compound, production and use as hiv inhibitors
HUP0500851A3 (en) Process for the preparation of rosuvastatin
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
AU2002340139A1 (en) Inhibitors of the egf receptor for the treatment of thyroid cancer
AU2002328952A1 (en) Irinotecan for treatment of cancer
AU2003254051A1 (en) Pyrazolopyrimidines as kinase inhibitors
AU2002352221A1 (en) Bicyclic n-arylamides
AU2002255918A1 (en) Human serine/threonine kinase
AU2003261204A1 (en) Pyrazolopyrimidines as kinase inhibitors
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU2003264673A1 (en) Use of isoflavones for promoting slimming
AU2002303145A1 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
AU2003223538A1 (en) Methods for the treatment of cancer
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU2003260983A1 (en) Processes for the preparation of s-(-)-amlodipine
AU2003250819A1 (en) Use of compounds that stimulate cgmp
AU2003297363A1 (en) Use of cathepsin k inhibitors for the treatment of glaucoma
AU2002330108A1 (en) 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
AU2002304883A1 (en) Device for the treatment of tumours
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2003299399A1 (en) Use of a specific inhibitor of the 5ht2b receptor for the treatment of cancer